Teachers Advisors LLC increased its stake in AveXis, Inc. (NASDAQ:AVXS) by 2.6% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 54,217 shares of the company’s stock after buying an additional 1,387 shares during the period. Teachers Advisors LLC’s holdings in AveXis were worth $4,122,000 at the end of the most recent quarter.
A number of other hedge funds also recently added to or reduced their stakes in the company. Pictet Asset Management Ltd. increased its stake in AveXis by 44.9% in the first quarter. Pictet Asset Management Ltd. now owns 153,606 shares of the company’s stock valued at $11,679,000 after buying an additional 47,588 shares in the last quarter. Spark Investment Management LLC increased its stake in AveXis by 504.1% in the first quarter. Spark Investment Management LLC now owns 89,400 shares of the company’s stock valued at $6,797,000 after buying an additional 74,600 shares in the last quarter. Bank of New York Mellon Corp increased its stake in AveXis by 27.8% in the first quarter. Bank of New York Mellon Corp now owns 62,922 shares of the company’s stock valued at $4,784,000 after buying an additional 13,691 shares in the last quarter. AXA bought a new stake in AveXis during the first quarter valued at $2,892,000. Finally, Emory University increased its stake in AveXis by 25.2% in the first quarter. Emory University now owns 37,283 shares of the company’s stock valued at $2,835,000 after buying an additional 7,502 shares in the last quarter. 91.85% of the stock is currently owned by institutional investors.
Shares of AveXis, Inc. (NASDAQ:AVXS) opened at 92.58 on Friday. The firm’s market capitalization is $2.96 billion. The firm’s 50-day moving average is $87.50 and its 200 day moving average is $75.29. AveXis, Inc. has a 52 week low of $31.55 and a 52 week high of $97.77.
ILLEGAL ACTIVITY WARNING: “Teachers Advisors LLC Buys 1,387 Shares of AveXis, Inc. (AVXS)” was first published by Community Financial News and is the property of of Community Financial News. If you are accessing this story on another site, it was copied illegally and republished in violation of US & international trademark & copyright law. The correct version of this story can be read at https://www.com-unik.info/2017/08/19/avexis-inc-avxs-shares-bought-by-teachers-advisors-llc-updated.html.
Several analysts have weighed in on AVXS shares. BMO Capital Markets reissued a “buy” rating and set a $123.00 target price on shares of AveXis in a research report on Friday, August 11th. Zacks Investment Research raised shares of AveXis from a “sell” rating to a “hold” rating in a research report on Thursday, July 13th. Morgan Stanley reissued an “overweight” rating and set a $118.00 target price on shares of AveXis in a research report on Wednesday, August 9th. Citigroup Inc. set a $100.00 price objective on shares of AveXis and gave the company a “buy” rating in a research note on Thursday, June 15th. Finally, Evercore ISI assumed coverage on shares of AveXis in a research note on Wednesday. They set an “outperform” rating and a $120.00 price objective for the company. Two equities research analysts have rated the stock with a hold rating and ten have given a buy rating to the company’s stock. AveXis currently has an average rating of “Buy” and a consensus price target of $102.45.
In other news, VP Sukumar Nagendran sold 1,780 shares of the firm’s stock in a transaction that occurred on Thursday, June 1st. The shares were sold at an average price of $70.91, for a total transaction of $126,219.80. Following the transaction, the vice president now directly owns 1,780 shares in the company, valued at $126,219.80. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Over the last 90 days, insiders have sold 5,340 shares of company stock worth $434,872. Insiders own 18.60% of the company’s stock.
AveXis Company Profile
AveXis, Inc is a clinical-stage gene therapy company. The Company operates through the developing and commercializing gene therapy treatments for patients suffering from neurological genetic diseases segment. The Company’s product candidate, AVXS-101, is its gene therapy product candidate that is in a Phase I clinical trial for the treatment of spinal muscular atrophy (SMA) Type 1, which is a genetic disorder characterized by motor neuron loss and associated muscle deterioration.
What are top analysts saying about AveXis Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for AveXis Inc. and related companies.